A metabolomic study of the PPARδ agonist GW501516 for enhancing running endurance in Kunming mice
Open Access
- 6 May 2015
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 9884
Abstract
Exercise can increase peroxisome proliferator-activated receptor-δ (PPARδ) expression in skeletal muscle. PPARδ regulates muscle metabolism and reprograms muscle fibre types to enhance running endurance. This study utilized metabolomic profiling to examine the effects of GW501516, a PPARδ agonist, on running endurance in mice. While training alone increased the exhaustive running performance, GW501516 treatment enhanced running endurance and the proportion of succinate dehydrogenase (SDH)-positive muscle fibres in both trained and untrained mice. Furthermore, increased levels of intermediate metabolites and key enzymes in fatty acid oxidation pathways were observed following training and/or treatment. Training alone increased serum inositol, glucogenic amino acids and branch chain amino acids. However, GW501516 increased serum galactose and β-hydroxybutyrate, independent of training. Additionally, GW501516 alone raised serum unsaturated fatty acid levels, especially polyunsaturated fatty acids, but levels increased even more when combined with training. These findings suggest that mechanisms behind enhanced running capacity are not identical for GW501516 and training. Training increases energy availability by promoting catabolism of proteins and gluconeogenesis, whereas GW501516 enhances specific consumption of fatty acids and reducing glucose utilization.Keywords
This publication has 34 references indexed in Scilit:
- PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011
- Regulation of Skeletal Muscle Physiology and Metabolism by Peroxisome Proliferator-Activated Receptor δPharmacological Reviews, 2009
- PPARδ in humans: genetic and pharmacological evidence for a significant metabolic functionCurrent Opinion in Lipidology, 2009
- Peroxisome Proliferator-Activated Receptor (PPAR)β /δ: A New Potential Therapeutic Target for the Treatment of Metabolic SyndromeCurrent Molecular Pharmacology, 2009
- PPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a homeExpert Opinion on Investigational Drugs, 2008
- Peroxisome Proliferator‐Activated Receptor δ‐Agonist, GW501516, Ameliorates Insulin Resistance, Improves Dyslipidaemia in Monosodium l‐Glutamate Metabolic Syndrome MiceBasic & Clinical Pharmacology & Toxicology, 2008
- AMPK and PPARδ Agonists Are Exercise MimeticsCell, 2008
- Low‐intensity exercise increases skeletal muscle protein expression of PPARδ and UCP3 in type 2 diabetic patientsDiabetes/Metabolism Research and Reviews, 2006
- Roles of peroxisome proliferator-activated receptor delta (PPARδ) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndromeBiochimie, 2004
- Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndromeProceedings of the National Academy of Sciences, 2003